XILIO THERAPEUTICS INC. - COMMON STOCK

0.6932

06-May-25 16:45:00

15 minutes delayed

Stocks

-0.0466

-6.30%

Today's range

0.6900 - 0.7294

ISIN

N/A

Source

NASDAQ

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

20 Jan 2022 07:30:00 By Nasdaq GlobeNewswire
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

06 Jan 2022 07:30:00 By Nasdaq GlobeNewswire
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

02 Dec 2021 07:30:00 By Nasdaq GlobeNewswire
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

12 Nov 2021 07:00:03 By Nasdaq GlobeNewswire
Xilio Therapeutics Announces Closing of Initial Public Offering

26 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.